IQVIA Q2 revenue beats estimates; outlook raised

IQVIA Holdings

28/07/2026 12:10

Overview
US clinical research and healthcare data firm's Q2 revenue rose 8.7%, beating analyst expectations
Q2 adjusted EPS grew 12.1% to $3.15, beating analyst expectations
Company raised full-year 2026 guidance for revenue, adjusted EBITDA and adjusted EPS

Outlook
IQVIA raises full-year 2026 revenue guidance to $17.275 bln-$17.475 bln
Company lifts 2026 Adjusted EBITDA forecast to $4.0 bln-$4.05 bln
IQVIA expects 2026 Adjusted Diluted EPS of $12.80-$13.00

Result Drivers
R&D SOLUTIONS BOOKINGS - Record net new bookings of $3.15 bln in R&D Solutions, up 19% year-over-year, supported revenue growth
COMMERCIAL SOLUTIONS GROWTH - Double-digit growth in patient solutions and commercial engagement, and high-single-digit growth in analytics and consulting drove Commercial Solutions revenue
AI ADOPTION - Increased adoption of AI solutions contributed to organic revenue growth in Commercial Solutions

Company press release: ID:nBw8r502ya

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$4.37 bln
$4.30 bln (17 Analysts)
Q2 Adjusted EPS
Beat
$3.15
$3.03 (18 Analysts)
Q2 EPS
 
$1.53
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for IQVIA Holdings Inc is $236.50, about 10.9% above its July 27 closing price of $213.22
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 13 three months ago

Reuters Recommended Reads
July 27 - UK's Science Group preliminary H1 core revenue falls; expects buyback to exceed £20 mln
July 27 - Universal Health Services cuts 2026 forecast on Medicaid reimbursement uncertainty
July 27 - AstraZeneca Q2 revenue rises 6% on demand for its cancer therapies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)